Developmental Funds

$560,871P30FY2013CANIH

Vanderbilt University, Nashville TN

Investigators

Linked publications, trials & patents

Trial NCT07016399 Trial NCT06593106 Trial NCT05501665 Trial NCT05361720 Trial NCT04765072 Trial NCT02702310 Trial NCT02685631 Trial NCT02677883 Trial NCT02676752 Trial NCT02672475 Trial NCT02658487 Trial NCT02600533 Trial NCT02489422 Trial NCT02480114 Trial NCT02457910 Trial NCT02448225 Trial NCT02440737 Trial NCT02374931 Trial NCT02359851 Trial NCT02324881 Trial NCT02296112 Trial NCT02269111 Trial NCT02240381 Trial NCT02236546 Trial NCT02170272 Trial NCT02151539 Trial NCT02148406 Trial NCT01996527 Trial NCT01928160 Trial NCT01901367 Trial NCT01660971 Trial NCT01230515 Trial NCT01198535 Trial NCT01141218 Trial NCT01098669 Trial NCT01098643 Trial NCT01096407 Trial NCT01096394 Trial NCT01096381 Trial NCT01077440 Trial NCT01031446 Trial NCT01013506 Trial NCT01009931 Trial NCT01007422 Trial NCT00993694 Trial NCT00993135 Trial NCT00987766 Trial NCT00984542 Trial NCT00984490 Trial NCT00983268 Trial NCT00957736 Trial NCT00949052 Trial NCT00930930 Trial NCT00900406 Trial NCT00900003 Trial NCT00899769 Trial NCT00899626 Trial NCT00899457 Trial NCT00899301 Trial NCT00899028 Trial NCT00898742 Trial NCT00898638 Trial NCT00898430 Trial NCT00898313 Trial NCT00897988 Trial NCT00897832 Trial NCT00897793 Trial NCT00897650 Trial NCT00897468 Trial NCT00897403 Trial NCT00897117 Trial NCT00896948 Trial NCT00896675 Trial NCT00892801 Trial NCT00875238 Trial NCT00840814 Trial NCT00837876 Trial NCT00835679 Trial NCT00801346 Trial NCT00765245 Trial NCT00755040 Trial NCT00675636 Trial NCT00670644 Trial NCT00670605 Trial NCT00670046 Trial NCT00666211 Trial NCT00656604 Trial NCT00653250 Trial NCT00651976 Trial NCT00651716 Trial NCT00647218 Trial NCT00626873 Trial NCT00625417 Trial NCT00625066 Trial NCT00616590 Trial NCT00601991 Trial NCT00573404 Trial NCT00550537 Trial NCT00544648 Trial NCT00533884

Abstract

Developmental funds provide an essential base of support for the strategic initiatives of the Vanderbiltlngram Cancer Center (VICC) consistent with its overall planning processes. During the current project period, this support was applied in three areas: 1) recruitment of new faculty, 2) support of pilot projects and 3) the development of a new shared resource. A total of nine new faculty members were provided with recruitment support; a significant number of them have obtained peer-reviewed funding. A total of 27 pilot projects were funded over the project period with a significant publication and subsequent funding record. Finally, developmental funds supported the Survey and Biospecimen Shared Resource, now being presented as an established shared resource in this application. Given the continued growth in the VICC overall research enterprise and the successful use of developmental funds in the current project period, a new request of $725,000 per year is felt to be justified. This would be allocated as $450,000 per year for new faculty recruitment in targeted strategic areas, including but not limited to cancer genetics, genomics and epigenetics, cancer drug discovery, personalized cancer medicine. Phase I investigations, cancer epidemiology and population-based research, cancer control and hematologic and neurologic malignancies. A request of $275,000 per year will support three types of pilot projects: 1) highly innovative projects focusing on proof-of-concept or translational research, 2) preliminary collaborative investigations leading to multi-investigator grants, and 3) projects that closely align to our strategic plan in order to enhance key initiatives. The VICC has a proven track record in the stewardship of these funds. The current request, in concert with the continued commitment of VICC discretionary funds, enables the Director to support activities critical to the sustained research excellence of the VICC.

View original record on NIH RePORTER →